[COVID-19 in the intensive care unit]

Pneumologie. 2024 May;78(5):330-345. doi: 10.1055/a-1854-2693. Epub 2024 May 17.
[Article in German]

Abstract

The acute respiratory failure as well as ARDS (acute respiratory distress syndrome) have challenged clinicians since the initial description over 50 years ago. Various causes can lead to ARDS and therapeutic approaches for ARDS/ARF are limited to the support or replacement of organ functions and the prevention of therapy-induced consequences. In recent years, triggered by the SARS-CoV-2 pathogen, numerous cases of acute lung failure (C-ARDS) have emerged. The pathophysiological processes of classical ARDS and C-ARDS are essentially similar. In their final stages of inflammation, both lead to a disruption of the blood-air barrier. Treatment strategies for C-ARDS, like classical ARDS, focus on supporting or replacing organ functions and preventing consequential damage. This article summarizes the treatment strategies in the intensive care unit.

Publication types

  • Review
  • English Abstract

MeSH terms

  • COVID-19* / prevention & control
  • COVID-19* / therapy
  • Critical Care* / methods
  • Humans
  • Intensive Care Units*
  • Respiratory Distress Syndrome* / etiology
  • Respiratory Distress Syndrome* / therapy